Medical Research Network

The operational challenges of #clinicaltrials are a long list of nuanced situations that are specific to each individual protocol, for each individual site and each individual patient. Sitting around the table with leaders in Clinical Operations, Patient Engagement and Recruitment, Supply Chain Management, Biostatistics, and others, we were able to gain a better understanding of the current #challenges faced by trialists trying to get new therapies to #patients. Click the link to read more about the key challenges and how to approach them  https://lnkd.in/ewBWdesP

It’s the final day of the Patient Recruitment for Rare Disease Summit! Our team has had an incredible experience and engaged in some inspiring conversations. Be sure to stop by and say hi to Irina Morris, MBA and Tina Lightle before the event wraps up. #patientsfirst

Approximately 20% of cancer trials fail as a result of inadequate enrollment, according to the American Cancer Society’s Cancer Action Network. Click the link below to explore these barriers and how Home Trial Support & Site Network solutions can help overcome them. https://lnkd.in/e2sewVdg #Oncology #ClincalTrials #PatientCentric #DecentralizedTrials

Will we see you at the Patient Recruitment for Rare Disease Trials Summit in Boston? The team is looking forward to connecting with leading experts to advance patient-focused strategies that accelerate #raredisease trial enrollment and access to ground breaking therapies. Click here to book some time in with the MRN team attending the summit https://lnkd.in/eWfbZMfM

The industry is navigating a complex web of challenges, with a noticeable decline in traditional investment streams and rising economic pressures. This is forcing companies to adopt more efficient, adaptable, and collaborative models in order to sustain #clinicaltrials. As the landscape evolves, #innovation in #trialdesign and delivery is essential. Click here to explore some of the strategic adaptations the industry should pay close attention to. https://lnkd.in/e4KYpMQT

Our team is heading to Seoul for the Outsourcing in Clinical Trials conference! We're looking forward to engaging discussions, sharing insights, and discovering innovative approaches to advancing clinical trials. Click here to schedule a meeting with our team at the event:  https://lnkd.in/eXJDC78q

MRN joins the PACT Consortium to define and measure the impact of decentralized clinical trials for the BioPharma industry. Todd McGrath, Chief Operating Officer and General Manager of Home Trial Support at MRN said: “With the clinical trial landscape becoming increasingly competitive, the complexity of protocols rising and Sponsors now under more pressure than ever to produce successful diversity action plans, it’s imperative that we examine how decentralizing clinical trials can deliver trial objectives while maintaining cost effectiveness. Being a part of this forum allows us to bring nearly 20 years of DCT learning to the table and examine the impact of DCT solutions that can further enhance how we build trials for Sponsors, sites and patients, while contributing to the industry as a whole - driving innovation that will result in more effective and efficient ways to conduct clinical trials. Click here to read more https://lnkd.in/e-tAW3_q #medicalresearch #dct #hybridtrials

Patients participating in clinical trials should be representative of the population that will receive the approved marketed drug. However, people of colour account for only 2 to 16% of trial participants. As an industry we must tackle key barriers to recruiting diverse patient populations, including: - Rigid trial designs - Over-reliance on the same trial sites - Failure to address patient-specific burdens As an industry stakeholder, what are your thoughts on how we can effectively overcome these challenges? Click here to read more https://lnkd.in/ejmNzT3w #diversityinclinicaltrials #patientcentric #hybridtrials

Except that is exactly what keeps happening. Sponsors and CROs are using the same sites for their #clinicaltrials, which means they are repeatedly returning to the same patient cohorts. This sees those patient cohort groups not only diminish more and more each time, but it also leads to a trend where there is limited to no true #representation of a real-world patient population. Diverse patient pools are key to ensuring trial results reflect real-world populations, improving the accuracy and relevance of outcomes. Click the link below to learn how MRN’s site network enables access to diverse patient populations, accelerating trial timelines and improving outcomes https://lnkd.in/euzEG89H

The FDA's four-part guidance series on patient-focused drug development (PFDD) aims to make trials more inclusive and effective by prioritizing what truly matters to patients. By centering trials around patient experiences, the FDA’s guidance helps improve #recruitment, #retention, and the overall quality of trial outcomes. Click here to read the full article, which explores how each FDA guidance is reshaping clinical trials to be more #patientcentric https://lnkd.in/dapXe8bb